BUZZ-Unicycive tumbles as FDA flags manufacturing issues with kidney disease drug** Shares of drug developer Unicycive Therapeutics UNCY.O fall 27% to 65 cents premarket
** UNCY says U.S. FDA has identified manufacturing issues with third-party vendor of its kidney disease drug, oxylanthanum carbonate
** Co says FDA cannot discuss drug labeling with UNCY until these issues are resolved
** Adds it is working to resolve FDA's concerns and is confident in drug's potential to treat hyperphosphatemia, which is condition where there are high phosphate levels in patients on dialysis
** Despite issues, final FDA decision is expected by original action date of June 28
** As of last close, stock up 13.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.